Header Logo

Connection

John Somberg to Humans

Back to Details
This is a "connection" page, showing publications John Somberg has written about Humans.
John Somberg
Connection Strength
2.896
Humans
  1. The Efficacy of Nitric Oxide-Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patients of African American and Hispanic Origin. Am J Med. 2023 10; 136(10):1035-1040.e11.
    View in: PubMed
    Score: 0.050
  2. The Bretylium Saga: A Novel "Old Drug" for Cardiac Resuscitation. Am J Cardiol. 2020 05 15; 125(10):1596-1598.
    View in: PubMed
    Score: 0.040
  3. Evaluating Serious Adverse Drug Reactions. Cardiology. 2018; 139(3):202.
    View in: PubMed
    Score: 0.035
  4. Adverse Reactions of Amiodarone on the Thyroid. Cardiology. 2016; 134(3):364-5.
    View in: PubMed
    Score: 0.031
  5. Angiotensin-Neprilysin Combinations Marketing Poly or Therapeutic Optimization. Am J Ther. 2015 Sep-Oct; 22(5):321.
    View in: PubMed
    Score: 0.029
  6. Retrospective Evaluation on the Analgesic Activities of 2 Compounded Topical Creams and Voltaren Gel in Chronic Noncancer Pain. Am J Ther. 2015 Sep-Oct; 22(5):342-9.
    View in: PubMed
    Score: 0.029
  7. Evaluation of the Effects of Different Energy Drinks and Coffee on Endothelial Function. Am J Cardiol. 2015 Nov 01; 116(9):1457-60.
    View in: PubMed
    Score: 0.029
  8. The Need for Stimulation. Am J Ther. 2015 Jul-Aug; 22(4):243.
    View in: PubMed
    Score: 0.029
  9. A Rapid Method to Evaluate Cardiac Repolarization Changes: The Effect of Two Coffee Strengths on the QT Interval. Cardiology. 2015; 131(3):203-8.
    View in: PubMed
    Score: 0.029
  10. Retrospective Study on the Analgesic Activity of a Topical (TT-CTAC) Cream in Patients With Diabetic Neuropathy and Other Chronic Pain Conditions. Am J Ther. 2015 May-Jun; 22(3):214-21.
    View in: PubMed
    Score: 0.029
  11. Lesson to be learned from the renal denervation trials. Am J Ther. 2015 May-Jun; 22(3):167-70.
    View in: PubMed
    Score: 0.029
  12. Computerization in medicine. Am J Ther. 2015 Mar-Apr; 22(2):89.
    View in: PubMed
    Score: 0.028
  13. The new year. Am J Ther. 2015 Jan-Feb; 22(1):1.
    View in: PubMed
    Score: 0.028
  14. The failing Ebola policy. Am J Ther. 2014 Nov-Dec; 21(6):441.
    View in: PubMed
    Score: 0.028
  15. Digoxin therapy for atrial fibrillation in the twenty-first century. Am J Ther. 2014 Sep-Oct; 21(5):325-6.
    View in: PubMed
    Score: 0.027
  16. OUS results, clinical studies and therapeutic innovation in America. Am J Ther. 2014 Jul-Aug; 21(4):233.
    View in: PubMed
    Score: 0.027
  17. International vs. hospital acquired infection. Am J Ther. 2014 May-Jun; 21(3):141.
    View in: PubMed
    Score: 0.027
  18. Courts, patents, litigation & patient care. Am J Ther. 2014 May-Jun; 21(3):142.
    View in: PubMed
    Score: 0.027
  19. Assessment of cardiovascular and noncardiovascular medical device recalls. Am J Cardiol. 2014 Jun 01; 113(11):1899-903.
    View in: PubMed
    Score: 0.026
  20. Clinical trials and their surprises. Am J Ther. 2014 Mar-Apr; 21(2):67.
    View in: PubMed
    Score: 0.026
  21. Guidelines for a new year. Am J Ther. 2014 Jan-Feb; 21(1):1.
    View in: PubMed
    Score: 0.026
  22. The conflict of interest charade. Am J Ther. 2013 Nov-Dec; 20(6):591.
    View in: PubMed
    Score: 0.026
  23. Health care in turmoil. Am J Ther. 2013 Sep-Oct; 20(5):459.
    View in: PubMed
    Score: 0.025
  24. The Supremes got it right. Am J Ther. 2013 Jul-Aug; 20(4):315.
    View in: PubMed
    Score: 0.025
  25. The dark side of implantable cardioverter defibrillator therapy. Cardiology. 2013; 124(4):213-5.
    View in: PubMed
    Score: 0.025
  26. The cart before the horse. Am J Ther. 2013 Mar-Apr; 20(2):127.
    View in: PubMed
    Score: 0.025
  27. Proposed accelerated FDA approvals for special medical use. Am J Ther. 2012 Nov; 19(6):393-4.
    View in: PubMed
    Score: 0.024
  28. Making America more competitive: a paradigm shift in drug and device development. Am J Ther. 2012 Sep; 19(5):315-6.
    View in: PubMed
    Score: 0.024
  29. The human microbiome and therapeutics. Am J Ther. 2012 Jul; 19(4):247.
    View in: PubMed
    Score: 0.023
  30. Is there an imperative for generic profiling to hasten the age of personalized medicine. Am J Ther. 2012 May; 19(3):163.
    View in: PubMed
    Score: 0.023
  31. Drug shortages and ensuring the U.S. supply of needed pharmaceuticals. Am J Ther. 2012 Mar; 19(2):65.
    View in: PubMed
    Score: 0.023
  32. Guidelines or 10 commandments. Am J Ther. 2012 Jan; 19(1):1.
    View in: PubMed
    Score: 0.023
  33. Drug and device trials: should we ask more. Am J Ther. 2011 Nov; 18(6):435.
    View in: PubMed
    Score: 0.022
  34. The impact of comorbidities on stroke prophylaxis strategies in atrial fibrillation patients. Am J Ther. 2011 Nov; 18(6):510-7.
    View in: PubMed
    Score: 0.022
  35. The device development pinata. Am J Ther. 2011 Sep; 18(5):339.
    View in: PubMed
    Score: 0.022
  36. Are we facilitating therapeutic innovation? Am J Ther. 2011 Jul; 18(4):279.
    View in: PubMed
    Score: 0.022
  37. Has the food and drug administration changed the drug approval process? Am J Ther. 2011 May; 18(3):179.
    View in: PubMed
    Score: 0.022
  38. Gender differences in cardiac repolarization following intravenous sotalol administration. J Cardiovasc Pharmacol Ther. 2012 Mar; 17(1):86-92.
    View in: PubMed
    Score: 0.022
  39. Inappropriate attack on device development. Am J Ther. 2011 Mar-Apr; 18(2):91.
    View in: PubMed
    Score: 0.021
  40. Have we maxed out on new therapies. Am J Ther. 2011 Mar-Apr; 18(2):91.
    View in: PubMed
    Score: 0.021
  41. From therapeutic nihilism to therapeutic success. Am J Ther. 2011 Jan; 18(1):1.
    View in: PubMed
    Score: 0.021
  42. The Food and Drug Administration's paternalism. Am J Ther. 2010 Nov-Dec; 17(6):533-4.
    View in: PubMed
    Score: 0.021
  43. The midodrine withdrawal. Am J Ther. 2010 Sep-Oct; 17(5):445.
    View in: PubMed
    Score: 0.021
  44. QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol. Cardiology. 2010; 116(3):219-25.
    View in: PubMed
    Score: 0.021
  45. Developing a safe intravenous sotalol dosing regimen. Am J Ther. 2010 Jul-Aug; 17(4):365-72.
    View in: PubMed
    Score: 0.020
  46. Device safety and effectiveness. Am J Ther. 2010 Jul-Aug; 17(4):357.
    View in: PubMed
    Score: 0.020
  47. Composite end points, black box warnings, and allegations of bias. Am J Ther. 2010 May-Jun; 17(3):233.
    View in: PubMed
    Score: 0.020
  48. Topics in clinical pharmacology: cardiovascular and diabetes mellitus. Dis Mon. 2010 Mar; 56(3):105-79.
    View in: PubMed
    Score: 0.020
  49. Is the device development process adequate. Am J Ther. 2010 Mar-Apr; 17(2):123-4.
    View in: PubMed
    Score: 0.020
  50. The hubris of science: defending the scientific process from political agendas. Am J Ther. 2010 Jan-Feb; 17(1):1.
    View in: PubMed
    Score: 0.020
  51. New advances and new questions in cardiovascular therapeutics. Am J Ther. 2009 Sep-Oct; 16(5):375-7.
    View in: PubMed
    Score: 0.019
  52. Medical isotope shortages. Am J Ther. 2009 Sep-Oct; 16(5):378.
    View in: PubMed
    Score: 0.019
  53. Health care reform. Am J Ther. 2009 Jul-Aug; 16(4):281-2.
    View in: PubMed
    Score: 0.019
  54. Supporting therapeutic innovation. Am J Ther. 2009 May-Jun; 16(3):203.
    View in: PubMed
    Score: 0.019
  55. Neurocardiogenic syncope. Cardiology. 2009; 114(1):47-9.
    View in: PubMed
    Score: 0.019
  56. The extrapolation of study results in the device approval process. Am J Cardiol. 2009 May 01; 103(9):1323-4.
    View in: PubMed
    Score: 0.019
  57. The dynamics of QT dispersion. Cardiology. 2009; 113(3):169-71.
    View in: PubMed
    Score: 0.018
  58. Evidence based or mechanism based therapeutics. Am J Ther. 2009 Jan-Feb; 16(1):1.
    View in: PubMed
    Score: 0.018
  59. The management of acute heart failure and diuretic therapy. Am J Ther. 2009 Jan-Feb; 16(1):93-7.
    View in: PubMed
    Score: 0.018
  60. The pleiotropic effects of ethacrynic acid. Am J Ther. 2009 Jan-Feb; 16(1):102-4.
    View in: PubMed
    Score: 0.018
  61. Therapeutic approaches to the treatment of edema and ascites: the use of diuretics. Am J Ther. 2009 Jan-Feb; 16(1):98-101.
    View in: PubMed
    Score: 0.018
  62. The clinical pharmacology of ethacrynic acid. Am J Ther. 2009 Jan-Feb; 16(1):86-92.
    View in: PubMed
    Score: 0.018
  63. The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology. 2009; 113(1):59-65.
    View in: PubMed
    Score: 0.018
  64. The drug eluting stent challenge. Am J Ther. 2008 Nov-Dec; 15(6):505.
    View in: PubMed
    Score: 0.018
  65. Licensing to prescribe. Am J Ther. 2008 Sep-Oct; 15(5):417-8.
    View in: PubMed
    Score: 0.018
  66. QT dispersion: still a useful measurement. Cardiology. 2009; 112(3):165-7.
    View in: PubMed
    Score: 0.018
  67. The sins of ghostwriting. Am J Ther. 2008 Jul-Aug; 15(4):297-8.
    View in: PubMed
    Score: 0.018
  68. Incidence and predictors of screen failures due to positive urine tests for alcohol, drugs of abuse, and cotinine among normal healthy research volunteers (NHRVs): analysis of data from 687 NHRVs screened at a large clinical pharmacology unit in the United States. Am J Ther. 2008 May-Jun; 15(3):214-20.
    View in: PubMed
    Score: 0.018
  69. The cholesterol hypothesis: questioned? Am J Ther. 2008 May-Jun; 15(3):292-5.
    View in: PubMed
    Score: 0.018
  70. Ventricular repolarization spectra. Cardiology. 2008; 111(3):207-8.
    View in: PubMed
    Score: 0.018
  71. Flecainide: safety and efficacy. Cardiology. 2008; 111(2):82.
    View in: PubMed
    Score: 0.017
  72. FDA user fees and innovation. Am J Ther. 2008 Mar-Apr; 15(2):97.
    View in: PubMed
    Score: 0.017
  73. Therapeutic hangups. Am J Ther. 2008 Jan-Feb; 15(1):1.
    View in: PubMed
    Score: 0.017
  74. First-in-Man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials. Am J Ther. 2007 Nov-Dec; 14(6):594-604.
    View in: PubMed
    Score: 0.017
  75. Screening drugs for QT prolongation. Am J Ther. 2007 Sep-Oct; 14(5):419-20.
    View in: PubMed
    Score: 0.017
  76. Mandatory post marketing studies. Am J Ther. 2007 Jul-Aug; 14(4):321.
    View in: PubMed
    Score: 0.017
  77. Patent foramen ovale closure devices: thoughts from the circulatory device advisory panel. Am J Cardiol. 2007 Sep 01; 100(5):905-6.
    View in: PubMed
    Score: 0.017
  78. Guilt by association. Am J Ther. 2007 May-Jun; 14(3):229-30.
    View in: PubMed
    Score: 0.016
  79. Biologic generics. Am J Ther. 2007 May-Jun; 14(3):230.
    View in: PubMed
    Score: 0.016
  80. The drug safety review process. Am J Ther. 2007 Mar-Apr; 14(2):119.
    View in: PubMed
    Score: 0.016
  81. Late stent thrombosis: problem or not? Am J Cardiol. 2007 Apr 01; 99(7):1020-3.
    View in: PubMed
    Score: 0.016
  82. The report of the Institute of Medicine on drug safety. Am J Ther. 2007 Jan-Feb; 14(1):1-2.
    View in: PubMed
    Score: 0.016
  83. The hypertension peril and drug development. Am J Ther. 2007 Jan-Feb; 14(1):2.
    View in: PubMed
    Score: 0.016
  84. The evaluation of the diuretic action of parenteral formulations of metolazone. Am J Ther. 2007 Jan-Feb; 14(1):25-9.
    View in: PubMed
    Score: 0.016
  85. Physician specific prescribing information. Am J Ther. 2006 Nov-Dec; 13(6):465.
    View in: PubMed
    Score: 0.016
  86. Surrogate endpoints and drug approval. Am J Ther. 2006 Sep-Oct; 13(5):388.
    View in: PubMed
    Score: 0.016
  87. Genetic drug targeting. Am J Ther. 2006 Jul-Aug; 13(4):289-90.
    View in: PubMed
    Score: 0.015
  88. Evaluation of a 12-lead digital Holter system for 24-hour QT interval assessment. Cardiology. 2006; 106(4):224-32.
    View in: PubMed
    Score: 0.015
  89. Risk assessment, drug approval, and liability. Am J Ther. 2006 May-Jun; 13(3):181-2.
    View in: PubMed
    Score: 0.015
  90. Pharmaceutical companies and medical therapeutics education. Am J Ther. 2006 Mar-Apr; 13(2):93.
    View in: PubMed
    Score: 0.015
  91. Letter from Konstantinos P. Letsas et al. - invited editorial comment. Cardiology. 2006; 105(3):148.
    View in: PubMed
    Score: 0.015
  92. Nesiritide: the wrong controversy. Am J Ther. 2005 Sep-Oct; 12(5):377-8.
    View in: PubMed
    Score: 0.015
  93. Chiral cardiovascular drugs: an overview. Am J Ther. 2005 Sep-Oct; 12(5):439-59.
    View in: PubMed
    Score: 0.015
  94. A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels. Am J Ther. 2005 Jul-Aug; 12(4):328-36.
    View in: PubMed
    Score: 0.014
  95. The new drug evaluation process: risk benefit ratio. Am J Ther. 2005 May-Jun; 12(3):199-200.
    View in: PubMed
    Score: 0.014
  96. Lessons learned from the COX-2 advisory hearings. Am J Ther. 2005 Mar-Apr; 12(2):105.
    View in: PubMed
    Score: 0.014
  97. The influence of extracellular acidosis on the effect of IKr blockers. J Cardiovasc Pharmacol Ther. 2005 Mar; 10(1):67-76.
    View in: PubMed
    Score: 0.014
  98. The politics of therapeutics. Am J Ther. 2004 Nov-Dec; 11(6):422.
    View in: PubMed
    Score: 0.014
  99. The pharmacologic treatment of heart failure. Am J Ther. 2004 Nov-Dec; 11(6):480-8.
    View in: PubMed
    Score: 0.014
  100. Drug trial registries. Am J Ther. 2004 Sep-Oct; 11(5):327.
    View in: PubMed
    Score: 0.014
  101. Obesity therapeutics in the shadows: editorial. Am J Ther. 2004 May-Jun; 11(3):155.
    View in: PubMed
    Score: 0.013
  102. Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. Am J Cardiol. 2004 Mar 01; 93(5):576-81.
    View in: PubMed
    Score: 0.013
  103. Should statins go OTC. Am J Ther. 2004 Jan-Feb; 11(1):1-2.
    View in: PubMed
    Score: 0.013
  104. Enhancement of myocardial vulnerability by atrial fibrillation. Am J Ther. 2004 Jan-Feb; 11(1):33-43.
    View in: PubMed
    Score: 0.013
  105. A case of herceptin cardiotoxicity. Am J Ther. 2004 Jan-Feb; 11(1):74-6.
    View in: PubMed
    Score: 0.013
  106. Therapeutics, drug pricing and innovation. Am J Ther. 2003 Nov-Dec; 10(6):381.
    View in: PubMed
    Score: 0.013
  107. The quest for an aqueous amiodarone. Am J Ther. 2003 Nov-Dec; 10(6):458-61.
    View in: PubMed
    Score: 0.013
  108. Clinical trials registries. Am J Ther. 2003 Sep-Oct; 10(5):309-10.
    View in: PubMed
    Score: 0.013
  109. Biomarker and surrogate endpoints. Am J Ther. 2003 Jul-Aug; 10(4):239-40.
    View in: PubMed
    Score: 0.013
  110. SARS challenges therapeutics. Am J Ther. 2003 May-Jun; 10(3):161.
    View in: PubMed
    Score: 0.012
  111. Hypertension therapeutics in turmoil. Am J Ther. 2003 Mar-Apr; 10(2):81-2.
    View in: PubMed
    Score: 0.012
  112. Free exchange of ideas. Am J Ther. 2003 Jan-Feb; 10(1):1.
    View in: PubMed
    Score: 0.012
  113. Pediatric drug development. Am J Ther. 2003 Jan-Feb; 10(1):2.
    View in: PubMed
    Score: 0.012
  114. Clinical therapeutic conference. Am J Ther. 2003 Jan-Feb; 10(1):78-80.
    View in: PubMed
    Score: 0.012
  115. Restricting physician prescribing. Am J Ther. 2002 Sep-Oct; 9(5):369.
    View in: PubMed
    Score: 0.012
  116. Genetic polymorphisms. Am J Ther. 2002 Jul-Aug; 9(4):271.
    View in: PubMed
    Score: 0.012
  117. Old drugs, new bottles, therapeutic advantage? Am J Ther. 2002 Jul-Aug; 9(4):273-4.
    View in: PubMed
    Score: 0.012
  118. Clinical research oversight. Am J Ther. 2002 Mar-Apr; 9(2):85.
    View in: PubMed
    Score: 0.011
  119. The generic conundrum. Am J Ther. 2002 Mar-Apr; 9(2):87-8.
    View in: PubMed
    Score: 0.011
  120. Usefulness of QT dispersion as an electrocardiographically derived index. Am J Cardiol. 2002 Feb 01; 89(3):291-4.
    View in: PubMed
    Score: 0.011
  121. Bioterrorism 2002. Am J Ther. 2002 Jan-Feb; 9(1):3.
    View in: PubMed
    Score: 0.011
  122. Rapid determination of partition coefficients between n-octanol/water for cardiovascular therapies. Am J Ther. 2002 Jan-Feb; 9(1):19-24.
    View in: PubMed
    Score: 0.011
  123. A challenge to America. Am J Ther. 2001 Nov-Dec; 8(6):383.
    View in: PubMed
    Score: 0.011
  124. A new therapeutic millennium [correction of millenium]. Am J Ther. 2001 Nov-Dec; 8(6):385-6.
    View in: PubMed
    Score: 0.011
  125. Stem-cell research. Am J Ther. 2001 Sep-Oct; 8(5):307.
    View in: PubMed
    Score: 0.011
  126. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther. 2001 Sep-Oct; 8(5):345-57.
    View in: PubMed
    Score: 0.011
  127. Class effects of pharmaceuticals and therapeutic interchangeability. Am J Ther. 2001 Jul-Aug; 8(4):221-2.
    View in: PubMed
    Score: 0.011
  128. Do we need to accredit clinical research? Am J Ther. 2001 Jul-Aug; 8(4):223-4.
    View in: PubMed
    Score: 0.011
  129. Proposed product labeling changes: does it really matter? Am J Ther. 2001 May-Jun; 8(3):145-6.
    View in: PubMed
    Score: 0.011
  130. Pediatric exclusivity and genericizing pharmaceuticals. Am J Ther. 2001 Mar-Apr; 8(2):79-80.
    View in: PubMed
    Score: 0.011
  131. Influence of electrolyte abnormalities on interlead variability of ventricular repolarization times in 12-lead electrocardiography. Am J Ther. 2001 Mar-Apr; 8(2):117-22.
    View in: PubMed
    Score: 0.011
  132. Are we overregulated? Am J Ther. 2001 Jan-Feb; 8(1):1-2.
    View in: PubMed
    Score: 0.011
  133. Clinical therapeutic conference: congestive heart failure therapy. Am J Ther. 2001 Jan-Feb; 8(1):65-72.
    View in: PubMed
    Score: 0.011
  134. The cost of therapy. Am J Ther. 2000 Nov; 7(6):343-4.
    View in: PubMed
    Score: 0.010
  135. Sudden death in athletes. Am J Ther. 2000 Nov; 7(6):399-403.
    View in: PubMed
    Score: 0.010
  136. A choice, not an echo. Am J Ther. 2000 Sep; 7(5):281.
    View in: PubMed
    Score: 0.010
  137. Is clinical research oversight adequate in the United States? Am J Ther. 2000 Sep; 7(5):283-4.
    View in: PubMed
    Score: 0.010
  138. Neurocardiogenic syncope with Addison's disease. Am J Ther. 2000 Sep; 7(5):328-31.
    View in: PubMed
    Score: 0.010
  139. Inhibition of Human Ether-A-Go-Go-Related Gene (hERG) Potassium Current by the Novel Sotalol Analogue, Soestalol. JACC Clin Electrophysiol. 2020 07; 6(7):756-759.
    View in: PubMed
    Score: 0.010
  140. Is the evidence right in evidence-based practice? Am J Ther. 2000 May; 7(3):149-50.
    View in: PubMed
    Score: 0.010
  141. What's gone wrong with clinical research. Am J Ther. 2000 Mar; 7(2):49-50.
    View in: PubMed
    Score: 0.010
  142. A federal solution a regulation for all. Am J Ther. 2000 Jan; 7(1):1-2.
    View in: PubMed
    Score: 0.010
  143. Medical judgment and therapeutics. Am J Ther. 1999 Nov; 6(6):291-2.
    View in: PubMed
    Score: 0.010
  144. Intravenous Sotalol for the Treatment of Ventricular Dysrhythmias in an Infant on Extracorporeal Membrane Oxygenation. Pediatr Cardiol. 2020 Feb; 41(2):418-422.
    View in: PubMed
    Score: 0.010
  145. Reorganizing the flow of scientific information: is the age of electronic journalism here? Am J Ther. 1999 Sep; 6(5):235-6.
    View in: PubMed
    Score: 0.010
  146. Effect of angiotensin-converting enzyme therapy on QT interval dispersion. Am J Ther. 1999 Sep; 6(5):257-61.
    View in: PubMed
    Score: 0.010
  147. International symposium on drug development. Am J Ther. 1999 Sep; 6(5):289.
    View in: PubMed
    Score: 0.010
  148. Biomarkers and surrogate endpoints. Am J Ther. 1999 Jul; 6(4):179-80.
    View in: PubMed
    Score: 0.010
  149. Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process. Am J Ther. 1999 May; 6(3):175-8.
    View in: PubMed
    Score: 0.009
  150. Reactions to prescribed drugs kill thousands annually. Am J Ther. 1998 May; 5(3):133.
    View in: PubMed
    Score: 0.009
  151. Effect of intracoronary balloon inflation at percutaneous transluminal coronary angioplasty on QT dispersion. Am Heart J. 1998 Mar; 135(3):519-22.
    View in: PubMed
    Score: 0.009
  152. Prostaglandin E1 : electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease. The Alprostadil Investigators. Am J Ther. 1997 Nov-Dec; 4(11-12):401-4.
    View in: PubMed
    Score: 0.008
  153. QT interval dispersion in healthy subjects and survivors of sudden cardiac death: circadian variation in a twenty-four-hour assessment. Am J Cardiol. 1997 May 01; 79(9):1190-3.
    View in: PubMed
    Score: 0.008
  154. Relation of left ventricular mass and QT dispersion in patients with systematic hypertension. Am J Cardiol. 1997 Feb 15; 79(4):508-11.
    View in: PubMed
    Score: 0.008
  155. Efficacy of Intravenous and Oral Sotalol in Pharmacologic Conversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiology. 2017; 136(1):52-60.
    View in: PubMed
    Score: 0.008
  156. Successful heart failure therapy is effective antiarrhythmia therapy. Am Heart J. 1996 May; 131(5):1048-50.
    View in: PubMed
    Score: 0.008
  157. Can nitroglycerin convert effort-induced angina in men into silent myocardial ischemia? Am J Cardiol. 1995 Aug 15; 76(5):337-9.
    View in: PubMed
    Score: 0.007
  158. Proarrhythmia: definition, risk factors, causes, treatment, and controversies. Am Heart J. 1994 Sep; 128(3):575-85.
    View in: PubMed
    Score: 0.007
  159. The clinical implications of first-pass metabolism: treatment strategies for the 1990s. J Clin Pharmacol. 1993 Jul; 33(7):670-3.
    View in: PubMed
    Score: 0.006
  160. A randomized comparative study of the electrophysiological and electrocardiographic effects of isradipine vs verapamil. Acta Anaesthesiol Scand Suppl. 1993; 99:43-7.
    View in: PubMed
    Score: 0.006
  161. Sharing regulatory review costs. J Clin Pharmacol. 1992 Oct; 32(10):867.
    View in: PubMed
    Score: 0.006
  162. A comparison of tablets with oral suspension formulation of dipyridamole in thallium myocardial imaging. J Clin Pharmacol. 1992 Jun; 32(6):546-52.
    View in: PubMed
    Score: 0.006
  163. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol. 1991 Nov; 31(11):1061-9.
    View in: PubMed
    Score: 0.006
  164. The role of electrophysiologic testing in the selection of amiodarone therapy. J Clin Pharmacol. 1989 May; 29(5):429-35.
    View in: PubMed
    Score: 0.005
  165. Usefulness of electrophysiologic studies in predicting drug efficacy in patients receiving amiodarone. Am J Cardiol. 1987 Nov 15; 60(14):1218.
    View in: PubMed
    Score: 0.004
  166. Encainide: a new and potent antiarrhythmic. Am Heart J. 1987 Oct; 114(4 Pt 1):826-35.
    View in: PubMed
    Score: 0.004
  167. The antiarrhythmic effects of d-sotalol. Am Heart J. 1987 Sep; 114(3):539-44.
    View in: PubMed
    Score: 0.004
  168. Evaluation of dosing interval and optimum dose of cibenzoline. J Clin Pharmacol. 1987 Sep; 27(9):666-72.
    View in: PubMed
    Score: 0.004
  169. Chronic flecainide therapy selected by electrophysiology testing of intravenous flecainide. Am Heart J. 1987 Jul; 114(1 Pt 1):18-25.
    View in: PubMed
    Score: 0.004
  170. Comparative efficacy of pirmenol and procainamide in a drug-resistant population with ventricular tachycardia. J Clin Pharmacol. 1987 Jul; 27(7):481-6.
    View in: PubMed
    Score: 0.004
  171. Refractory ventricular tachycardia with flecainide. Am Heart J. 1986 Jul; 112(1):174-5.
    View in: PubMed
    Score: 0.004
  172. The treatment of ventricular rhythm disturbances. Am Heart J. 1986 Jun; 111(6):1162-76.
    View in: PubMed
    Score: 0.004
  173. Antiarrhythmic efficacy of ethmozine in patients with ventricular tachycardia as determined by programmed electrical stimulation. Am Heart J. 1986 Apr; 111(4):661-6.
    View in: PubMed
    Score: 0.004
  174. Antiarrhythmic drug efficacy at electrophysiology testing: predictive effectiveness of procainamide and flecainide. Am Heart J. 1986 Apr; 111(4):632-8.
    View in: PubMed
    Score: 0.004
  175. Lorcainide therapy in a cardiac arrest population. Am Heart J. 1986 Apr; 111(4):648-53.
    View in: PubMed
    Score: 0.004
  176. Prophylactic tocainide or lidocaine in acute myocardial infarction. Am J Cardiol. 1986 Mar 01; 57(8):527-31.
    View in: PubMed
    Score: 0.004
  177. QT prolongation and the antiarrhythmic efficacy of amiodarone. J Am Coll Cardiol. 1986 Jan; 7(1):142-7.
    View in: PubMed
    Score: 0.004
  178. Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease. Am J Cardiol. 1985 Nov 15; 56(13):877-81.
    View in: PubMed
    Score: 0.004
  179. The clinical significance of polymorphic ventricular tachycardia provoked at electrophysiologic testing. Am Heart J. 1985 Jul; 110(1 Pt 1):17-24.
    View in: PubMed
    Score: 0.004
  180. The arrhythmogenicity of antiarrhythmic agents. Am Heart J. 1985 May; 109(5 Pt 1):1090-7.
    View in: PubMed
    Score: 0.004
  181. Antiarrhythmic effects of cibenzoline. Am Heart J. 1985 Apr; 109(4):827-33.
    View in: PubMed
    Score: 0.004
  182. Therapy for late post infarction ventricular tachycardia. Angiology. 1985 Mar; 36(3):181-90.
    View in: PubMed
    Score: 0.004
  183. Prolonged repolarization: a historical perspective. Am Heart J. 1985 Feb; 109(2):395-8.
    View in: PubMed
    Score: 0.004
  184. Antiarrhythmic drug therapy. Recent advances and current status. Cardiology. 1985; 72(5-6):329-48.
    View in: PubMed
    Score: 0.003
  185. Prolongation of QT interval and antiarrhythmic action of bepridil. Am Heart J. 1985 Jan; 109(1):19-27.
    View in: PubMed
    Score: 0.003
  186. Long term lorcainide therapy guided by electrophysiology studies. Acta Cardiol. 1985; 40(6):621-36.
    View in: PubMed
    Score: 0.003
  187. Flecainide: long-term treatment using a reduced dosing schedule. Am J Cardiol. 1985 Jan 01; 55(1):79-83.
    View in: PubMed
    Score: 0.003
  188. New directions in antiarrhythmic drug therapy. Am J Cardiol. 1984 Aug 13; 54(4):8B-17B.
    View in: PubMed
    Score: 0.003
  189. New directions in antiarrhythmic drug therapy: the development of a promising new agent, lorcainide. Am J Cardiol. 1984 Aug 13; 54(4):1B.
    View in: PubMed
    Score: 0.003
  190. Lorcainide therapy for the high-risk patient post myocardial infarction. Am J Cardiol. 1984 Aug 13; 54(4):37B-42B.
    View in: PubMed
    Score: 0.003
  191. Evaluation of lorcainide in patients with symptomatic ventricular tachycardia. Am J Cardiol. 1984 Aug 13; 54(4):43B-48B.
    View in: PubMed
    Score: 0.003
  192. Comparison of noninvasive arrhythmia induction techniques with electrophysiologic studies and evaluation of lorcainide in patients with symptomatic ventricular tachycardia. Am J Cardiol. 1984 Aug 13; 54(4):49B-54B.
    View in: PubMed
    Score: 0.003
  193. Antiarrhythmic action of bethanidine. Am J Cardiol. 1984 Aug 01; 54(3):343-6.
    View in: PubMed
    Score: 0.003
  194. New approaches to drug selection and serial drug testing. J Clin Pharmacol. 1984 Jul; 24(7):320-7.
    View in: PubMed
    Score: 0.003
  195. Pacing termination of ventricular tachycardia: influence of antiarrhythmic-slowed ectopic rate. Am Heart J. 1984 Apr; 107(4):638-43.
    View in: PubMed
    Score: 0.003
  196. Flecainide toxicity. Am J Cardiol. 1984 Jan 15; 53(2):329-30.
    View in: PubMed
    Score: 0.003
  197. Hypercalcemia, arrhythmia, and mood stabilizers. J Clin Psychopharmacol. 2000 Apr; 20(2):260-4.
    View in: PubMed
    Score: 0.003
  198. Lithium, hypercalcemia, and arrhythmia. J Clin Psychopharmacol. 1998 Oct; 18(5):420-3.
    View in: PubMed
    Score: 0.002
  199. KCNE1 mutations cause jervell and Lange-Nielsen syndrome. Nat Genet. 1997 Nov; 17(3):267-8.
    View in: PubMed
    Score: 0.002
  200. Proarrhythmia of nonantiarrhythmic drugs. Am Heart J. 1993 Jul; 126(1):201-5.
    View in: PubMed
    Score: 0.002
  201. Electrophysiology of Ethmozine (moricizine HCl) for ventricular tachycardia. Am J Cardiol. 1987 Oct 16; 60(11):67F-72F.
    View in: PubMed
    Score: 0.001
  202. Safety and efficacy of flestolol, a new ultrashort-acting beta-adrenergic blocking agent, for supraventricular tachyarrhythmias. Am J Cardiol. 1986 Nov 01; 58(10):1005-8.
    View in: PubMed
    Score: 0.001
  203. Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses. J Am Coll Cardiol. 1986 Oct; 8(4):752-62.
    View in: PubMed
    Score: 0.001
  204. Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias. J Am Coll Cardiol. 1986 Jan; 7(1):9-16.
    View in: PubMed
    Score: 0.001
  205. Pharmacokinetics of oral cibenzoline in arrhythmia patients. Clin Pharmacokinet. 1985 Mar-Apr; 10(2):178-86.
    View in: PubMed
    Score: 0.001
  206. Cibenzoline plasma concentration and antiarrhythmic effect. Clin Pharmacol Ther. 1984 Mar; 35(3):307-16.
    View in: PubMed
    Score: 0.001
  207. Refractory heart failure. Comparison of time course of action of sublingual nitroglycerin and isosorbide dinitrate, oral or sublingual. N Y State J Med. 1978 May; 78(6):888-9.
    View in: PubMed
    Score: 0.001
  208. Role of the nervous system in the genesis of cardiac rhythm disorders. Am J Cardiol. 1976 Jun; 37(7):1111-3.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.